Earnings call transcript: Haleon Q4 2025 misses expectations, stock dips

Haleon PLC announced its fiscal year 2025 earnings results, revealing a 3% growth in organic sales that fell short of the company's previous guidance, causing the stock to drop 3.16% in premarket trading as investors reacted to unexpected challenges in the cold and flu category and tough market conditions in North America. The global healthcare and consumer goods company had previously projected stronger growth for the fiscal year, making the 3% organic sales increase particularly disappointing. The underperformance was most notable in North America, where the company faced intensified competition and challenging market dynamics. Additionally, the cold and flu product category, which typically sees seasonal demand, failed to meet expectations, contributing to the overall shortfall. The earnings announcement comes at a critical time for Haleon as it continues to navigate post-pandemic market conditions and changing consumer behavior.